-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of the State Food and Drug Administration showed that Suzhou Erye Pharmaceutical entered the administrative approval stage by imitating Class 4 rivaroxaban tablets
.
According to data from Minet.
com, global sales of rivaroxaban in 2021 will exceed 8 billion US dollars; terminal sales in Chinese public medical institutions will exceed 3 billion yuan in 2020, with a year-on-year increase of 56.
57% in the first half of 2021
.
Rivaroxaban is an oral anticoagulant that directly inhibits factor Xa jointly developed by Bayer and Johnson & Johnson, with global sales exceeding $8 billion in 2021
.
Terminal rivaroxaban tablet sales in China's public medical institutions in recent years (unit: 100 million yuan) Source: MINET And the sales of terminal rivaroxaban tablets in township health centers (referred to as Chinese public medical institutions) exceeded 3 billion yuan; in the first half of 2021, it increased by 56.
57% year-on-year, and it is the TOP1 product of antithrombotic drugs.
Among them, Bayer has the largest market share
.
2021H1 China's public medical institutions' terminal antithrombotic drug products TOP5 Source: Minet.
com China's public medical institutions' terminal competition landscape At present, nearly 30 companies have the production approval of rivaroxaban tablets, Yichang Renfu Pharmaceutical, Tiandi Hengyi Pharmaceutical, More than 20 companies, including Lepu Pharmaceuticals and Jiangsu Tasly Diyi Pharmaceuticals, are under review, while Suzhou Erye Pharmaceutical has entered the stage of administrative approval
.
Source: State Food and Drug Administration official website, Minet database
.
According to data from Minet.
com, global sales of rivaroxaban in 2021 will exceed 8 billion US dollars; terminal sales in Chinese public medical institutions will exceed 3 billion yuan in 2020, with a year-on-year increase of 56.
57% in the first half of 2021
.
Rivaroxaban is an oral anticoagulant that directly inhibits factor Xa jointly developed by Bayer and Johnson & Johnson, with global sales exceeding $8 billion in 2021
.
Terminal rivaroxaban tablet sales in China's public medical institutions in recent years (unit: 100 million yuan) Source: MINET And the sales of terminal rivaroxaban tablets in township health centers (referred to as Chinese public medical institutions) exceeded 3 billion yuan; in the first half of 2021, it increased by 56.
57% year-on-year, and it is the TOP1 product of antithrombotic drugs.
Among them, Bayer has the largest market share
.
2021H1 China's public medical institutions' terminal antithrombotic drug products TOP5 Source: Minet.
com China's public medical institutions' terminal competition landscape At present, nearly 30 companies have the production approval of rivaroxaban tablets, Yichang Renfu Pharmaceutical, Tiandi Hengyi Pharmaceutical, More than 20 companies, including Lepu Pharmaceuticals and Jiangsu Tasly Diyi Pharmaceuticals, are under review, while Suzhou Erye Pharmaceutical has entered the stage of administrative approval
.
Source: State Food and Drug Administration official website, Minet database
